GE HealthCare Technologies Inc. (NASDAQ:GEHC) Shares Acquired by Foresight Capital Management Advisors Inc.

Foresight Capital Management Advisors Inc. boosted its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 15.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,382 shares of the company’s stock after buying an additional 460 shares during the quarter. Foresight Capital Management Advisors Inc.’s holdings in GE HealthCare Technologies were worth $264,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Pinnacle Bancorp Inc. lifted its stake in shares of GE HealthCare Technologies by 107.8% during the 4th quarter. Pinnacle Bancorp Inc. now owns 771 shares of the company’s stock worth $60,000 after purchasing an additional 400 shares during the period. CHURCHILL MANAGEMENT Corp raised its position in shares of GE HealthCare Technologies by 4.4% in the 4th quarter. CHURCHILL MANAGEMENT Corp now owns 107,427 shares of the company’s stock worth $8,399,000 after buying an additional 4,573 shares during the period. Avity Investment Management Inc. raised its position in shares of GE HealthCare Technologies by 6.8% in the 4th quarter. Avity Investment Management Inc. now owns 379,078 shares of the company’s stock worth $29,636,000 after buying an additional 24,236 shares during the period. Thurston Springer Miller Herd & Titak Inc. raised its position in shares of GE HealthCare Technologies by 26.0% in the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,304 shares of the company’s stock worth $102,000 after buying an additional 269 shares during the period. Finally, Park Avenue Securities LLC raised its position in shares of GE HealthCare Technologies by 9.7% in the 4th quarter. Park Avenue Securities LLC now owns 4,450 shares of the company’s stock worth $348,000 after buying an additional 392 shares during the period. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analysts Set New Price Targets

GEHC has been the subject of several recent research reports. BTIG Research upgraded GE HealthCare Technologies from a “neutral” rating to a “buy” rating and set a $100.00 price target for the company in a report on Wednesday, September 18th. Wells Fargo & Company increased their price target on GE HealthCare Technologies from $95.00 to $96.00 and gave the company an “overweight” rating in a report on Thursday, October 31st. UBS Group downgraded GE HealthCare Technologies from a “neutral” rating to a “sell” rating and lowered their price target for the company from $84.00 to $74.00 in a report on Thursday, September 26th. Jefferies Financial Group upgraded GE HealthCare Technologies from a “hold” rating to a “buy” rating and increased their price target for the company from $95.00 to $103.00 in a report on Wednesday, January 8th. Finally, Evercore ISI raised their target price on GE HealthCare Technologies from $98.00 to $102.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $96.00.

GE HealthCare Technologies Stock Performance

Shares of NASDAQ GEHC opened at $83.66 on Thursday. The company has a quick ratio of 0.98, a current ratio of 1.23 and a debt-to-equity ratio of 1.12. The firm’s 50-day moving average price is $82.13 and its two-hundred day moving average price is $84.27. GE HealthCare Technologies Inc. has a 52-week low of $71.31 and a 52-week high of $94.55. The stock has a market capitalization of $38.22 billion, a P/E ratio of 22.98, a P/E/G ratio of 2.80 and a beta of 1.11.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its earnings results on Wednesday, October 30th. The company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.06 by $0.08. GE HealthCare Technologies had a net margin of 8.56% and a return on equity of 25.19%. The firm had revenue of $4.86 billion for the quarter, compared to analysts’ expectations of $4.87 billion. During the same quarter last year, the company posted $0.99 earnings per share. GE HealthCare Technologies’s revenue was up .9% on a year-over-year basis. As a group, sell-side analysts forecast that GE HealthCare Technologies Inc. will post 4.3 earnings per share for the current year.

GE HealthCare Technologies Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Tuesday, January 14th will be issued a $0.035 dividend. The ex-dividend date of this dividend is Tuesday, January 14th. This represents a $0.14 dividend on an annualized basis and a yield of 0.17%. This is a boost from GE HealthCare Technologies’s previous quarterly dividend of $0.03. GE HealthCare Technologies’s dividend payout ratio (DPR) is currently 3.30%.

Insider Activity

In other news, CEO Roland Rott sold 3,577 shares of GE HealthCare Technologies stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $86.48, for a total transaction of $309,338.96. Following the sale, the chief executive officer now owns 24,298 shares of the company’s stock, valued at approximately $2,101,291.04. The trade was a 12.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.27% of the company’s stock.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.